Vaccine stocks fall after RFK Jr.'s HHS nomination advances - Breaking The News

Vaccine stocks fall after RFK Jr.'s HHS nomination advances

4 February

1 min read

EPA-EFE/CLEMENS BILAN

Shares of vaccine makers, including Moderna, Pfizer, and BioNTech, dipped Tuesday after the Senate Finance Committee advanced Robert F. Kennedy Jr.'s nomination for Health and Human Services secretary.

The 14-13 party-line vote moved the controversial pick to the Senate floor. Kennedy, known for his skepticism of vaccines, has drawn sharp criticism for his previous comments on vaccine safety.

At 10:41 am ET, Moderna's stock fell 5.11% to $34.68, BioNTech dropped 2.97% to $116.26, and Pfizer slipped 1.77% to $25.73.

kennedy pfizer biontech moderna

Related Stocks

BioNTech - Americ...

Pfizer

Moderna

Pfizer secures $10B Metsera takeover

8 November

Pfizer reached a deal to acquire US obesity-drug biotech Metsera worth approximately $10 billion, successfully sealing the deal after fierce competition with Novo Nordisk."We are pleased that we and Metsera have agreed to these revised terms, which will provide immediate and certain value to Metsera’s shareholders," Pfizer said. Under the deal, the pharmaceutical giant agreed to pay $65.60 per share in cash, plus a contingent value right of a maximum...

Moderna's Q3 revenue slumps 45% to $1.0 billion

6 November

Moderna Inc. revealed on Thursday that its total revenue for the third quarter of fiscal 2025 landed at $1.0 billion, declining 45% from the same period a year ago. The drop was largely attributed to an $847 million, or 47%, fall in net product sales, primarily reflecting reduced demand for COVID vaccines.In the reported period, the biotechnology giant reported a $200 million net loss, compared with a profit of $13 million a year earlier. Its diluted loss per share...

Pfizer, Novo Nordisk said to raise bids for Metsera

4 November

Pfizer and Novo Nordisk both raised their bids for US biotech Metsera, escalating one of the fiercest takeover battles in the obesity-drug sector. The Financial Times reported on Tuesday that the improved offers from both companies are expected to be disclosed in a regulatory filing later in the day.Novo Nordisk last week topped Pfizer's earlier agreement with a proposal worth up to $9 billion, triggering a legal and commercial standoff between the two...

Pfizer reports Q3 sales of $16.7 billion, down 6%

4 November

Pfizer Inc. announced on Tuesday that its revenue for the third quarter of 2025 fell by 6% annually to $16.7 billion. Net income dropped 21% to $3.5 billion, while the diluted earnings per share (EPS) also lost 21% year-on-year, landing at $0.62. The pharma giant reaffirmed its full-year 2025 revenue guidance of $61 billion to $64 billion and raised its diluted EPS outlook to between $3 and $3.15."I am proud of Pfizer's leadership as the first in our industry to reach an...

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.